This review focuses on the clinical evidence on whether individuals with acute myelogenous leukemia (AML) in first remission should undergo an allogeneic hematopoietic cell transplant (HCT) versus receiving post-remission chemotherapy (or both). The authors address four common clinical questions: 1) Do only individuals achieving second remission benefit from a transplant? 2) Is allogeneic HCT the only effective therapy for relapse? 3) Can we accurately predict which individuals with AML in first remission need a transplant? and 4) What is the clinical usefulness of detecting minimal residual disease in patients achieving first remission?
Review: HCT for Patients with AML in First Remission